ClinicalTrials.gg
CompletedNCT05726136FC-VEUpdated Nov 10, 2026

Fluid Challenge and Plasma Volume, During Surgery

A Phase 4 interventional study of acetated Ringers and albumin 5% in Colorectal Cancer, Urologic Cancer and Gynecologic Cancer, sponsored by Joachim Zdolsek. Completed at 1 site in Sweden. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Joachim Zdolsek · Phase 4, Interventional, and Treatment

How we know

Updated Nov 10, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 124 studies in Colorectal Neoplasms with a site in Sweden — 27 open to participants now, 38 under way, 10 of them phase 3. Colorectal Neoplasms · Sweden.

Enrollment
68th of 89
65 · median 215
Started
2023
with 7 others
Phase 4
3 of 124
none open now
Registered
99th of 124
by date

Among the 124 studies in Colorectal Neoplasms with a site in Sweden, this one is the 68th largest by enrollment of the 89 interventional ones that give a count, is one of 8 that started in 2023, is one of 3 in phase 4, and was the 99th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

27 of the 124 studies in Colorectal Neoplasms with a site in Sweden are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 124 studies in Colorectal Neoplasms with a site in Sweden, or all of them as a file.
02

Study summary

A short bolus infusion of fluid, called "fluid challenge" is commonly recommended for fluid treatment during longer surgery. However a prolonged increase of the blood volume is a prerequisite to recommend the technique. The purpose with the study is to examine the plasma expanding effect of three different fluid challenge strategies (acetated Ringers 4 ml/kg body weight, albumin 5% 4 ml/kg body weight or albumin 20% 1 ml/kg body weight), using hemoglobin as a dilution indicator.

Read the detailed description

60 patients scheduled for laparoscopic abdominal surgery, with a duration exceeding 90 minutes will be included in the study. These are randomized to three different groups (20 in each groups): The first group of patients will receive boluses of acetated Ringers 4 ml/kg body weight. The second albumin 4 ml/kg body weight and the third group albumin 20% 1 ml/kg body weight.

Hemoglobin, albumin and colloid osmotic pressure (COP) is sampled the day before surgery and in the morning directly prior to the anesthesia. Bioimpedance, urine osmolality and urine-creatinin are also measured. After induction of surgery a Cardio Q probe is inserted threw the nose into the esophagus, for circulatory measurements. Initial/baseline blood samples are taken after insufflation of carbon dioxide to the abdomen. Before every bolus of fluid and 5, (10), 15, 20, 30, 40, (50) and (60) minutes new blood samples are taken for determination of hemoglobin, albumin and COP. Artery blood gases are sampled 15 minutes after every infusion or depending on the clinical need.

03

Conditions studied

  • Colorectal Cancer
  • Urologic Cancer
  • Gynecologic Cancer
  • Colorectal Disorders
  • Benign Neoplasm

Keywords

  • laparoscopic surgery, fluid therapy, plasma volume
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written consent to participate in the study
  • For women: relevant , menopausal or a negative pregnancy test.
  • ASA category I to III
  • Laparoscopic abdominal surgery, with a duration of at least 90 minutes.
  • 18 to 85 years

Exclusion criteria

Exclusion Criteria:

  • Patients with known cardiac failure
  • \<18 or >85 years
  • known allergy to albumin
  • extracellular hyperhydration or hypervolemia
  • kidney failure
  • pregnancy or planned pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    acetated Ringers

    The circulatory effect of a bolus infusion with 4 ml/kg body weight of acetated Ringers will be studied. If cardiac output increase with 10% a second bolus will be infused and further studied.

    Drug: acetated Ringers

  • Experimental
    albumin 5%

    The circulatory effect of a bolus infusion with 4 ml/kg body weight of Albumin 5% will be studied. If cardiac output increases with 10% a second bolus will be infused and further studied.

    Drug: albumin 5%

  • Experimental
    albumin 20%

    The circulatory effect of a bolus infusion with 1 ml/kg body weight of Albumin 20% will be studied. If cardiac output increase with 10% a second bolus will be infused and further studied.

    Drug: albumin 20%

Interventions

  • DrugRinger's acetateStudies of Ringer's acetateRinger's acetate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    After insufflation of carbon dioxide during an abdominal laparoscopic procedure, the first fluid bolus is infused. Circulatory and volume effects are studied. If cardiac output increase a second bolus is infused and studied.

    Also known as: Ringer's acetate, ringer acetate, acetate Ringer´s

  • DrugAlbuminsStudies of AlbuminsAlbumins pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    After insufflation of carbon dioxide during an abdominal laparoscopic procedure, the first bolus of fluid is infused. Circulatory and volume effects are studied. If cardiac output increases a second bolus is infused and studied.

    Also known as: Albumin (Human) 5%, Human Albumin 5%

  • DrugAlbuminsStudies of AlbuminsAlbumins pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    After insufflation of carbon dioxide during an abdominal laparoscopic procedure, the first bolus of fluid is infused. Circulatory and volume effects are studied. If cardiac output increases a second bolus is infused and studied.

    Also known as: Human Albumin 20%, Albumin (Human) 20%

06

What researchers measure

Primary outcomes

  1. Plasma volume expansion after a fluid bolus

    Plasma volume using hemoglobin as an indicator of dilution

    Time frame: 60 minutes after an intravenous fluid bolus

Secondary outcomes

  1. Fluid Balance

    Calculations of fluid balance

    Time frame: 18 to 24 hours

  2. Stroke Volume

    Change in stroke volume, measured with Cardio Q (oesophageal Doppler monitoring (ODM))

    Time frame: 60 minutes after an intravenous fluid bolus

  3. Arterial Blood Pressure

    Mean Arterial Pressure, measured with an arterial line.

    Time frame: 60 minutes after an intravenous fluid bolus

  4. Heart Rate

    Heart rate, measured with ECG and pulseoximeter.

    Time frame: 60 minutes after an intravenous fluid bolus

  5. Bioimpedance

    Bioimpedance measures, resistance and impedance converted to volume of body fluid compartments.

    Time frame: 18 to 24 hours

  6. Serum Creatinin

    Serum Creatinin as a measure of kidney function

    Time frame: 18 to 24 hours

  7. arterial pH

    Influence of a fluid bolus on arterial blood gases

    Time frame: 60 minutes after an intravenous fluid bolus

  8. arterial Base Excess

    Influence of a fluid bolus on arterial blood gases

    Time frame: 60 minutes after an intravenous fluid bolus

  9. arterial serum sodium

    Influence of a fluid bolus on Sodium concentration

    Time frame: 60 minutes after an intravenous fluid bolus

  10. arterial serum chloride

    Influence of a fluid bolus on Chloride concentrations

    Time frame: 60 minutes after an intravenous fluid bolus

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Individual de-identified results will be shared, when results are published.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Jun 2026, 31 months.

Of 38 phase 4 interventional studies under Colorectal Neoplasms, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 57. This study's 31 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Oct 2026 → Jun 2026 and completion Oct 2026 → Jun 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2023
First posted
Feb 13, 2023
StartActual
Oct 23, 2023
Primary completionActual
Jun 10, 2026was Oct 2026
CompletionActual
Jun 10, 2026was Oct 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 10, 2026
Primary completion
Oct 31, 2026→Jun 10, 2026 (actual)
Nov 10, 2026
Study completion
Oct 31, 2026→Jun 10, 2026 (actual)
Nov 10, 2026
Enrollment
60 (estimated)→65 (actual)
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Recruiting→Completed
    Primary completion Oct 31, 2026→Jun 10, 2026 (now actual)
    Study completion Oct 31, 2026→Jun 10, 2026 (now actual)
    Enrollment 60 (estimated)→65 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05726136
Lead sponsor
Joachim Zdolsek
Responsible party
Joachim Zdolsek (consultant, assoc prof, University Hospital, Linkoeping) — Sponsor-investigator
First posted
Feb 13, 2023
Start date
Oct 23, 2023
Primary completion
Jun 10, 2026
Completion
Jun 10, 2026
Last update
Nov 10, 2026

Study contacts

Joachim Zdolsek, MD PhD
principal investigator · Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ringer's acetate · Albumins

Start the discussion